Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$169 Mln
Revenue (TTM)
$57 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
26.4
Industry P/E
37.47
EV/EBITDA
-0.2
Div. Yield
0 %
Debt to Equity
2.9
Book Value
$--
EPS
$-0.9
Face value
--
Shares outstanding
21,854,900
CFO
$-133.61 Mln
EBITDA
$-138.92 Mln
Net Profit
$-194.46 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Exagen (XGN)
| 79.5 | 22.5 | 103.3 | 260.8 | 14.0 | -11.8 | -- |
|
BSE Sensex*
| 4.0 | -1.1 | 8.1 | 5.3 | 16.6 | 18.9 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|
|
Exagen (XGN)
| 104.8 | -17.1 | -79.4 | -11.9 | -48.0 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Exagen (XGN)
|
7.4 | 168.9 | 56.7 | -15.5 | -17.7 | -160.9 | -- | 26.4 |
| 546.1 | 8,080.6 | 2,489.0 | 308.7 | 16.3 | 25.5 | 26.8 | 6.8 | |
| 102.5 | 5,290.1 | 895.6 | 95.2 | 9.8 | 33.4 | 56.1 | 16.8 | |
| 135.8 | 10,417.5 | 12,968.5 | 859.6 | 15.0 | -- | 13.7 | 21.6 | |
| 119.8 | 12,188.4 | 5,512.6 | 494.7 | 17.0 | 16.3 | 24.9 | 5.6 | |
| 31.6 | 5,213.7 | 5,185.1 | 213.8 | 6.6 | 15.4 | 25.5 | 3.9 | |
| 57.1 | 4,309.0 | 1,869.4 | -14.6 | 4.8 | -5.7 | -- | 4.8 | |
| 10.9 | 3,108.2 | 1,106.8 | 24.8 | 21.6 | 5.6 | 121.7 | 7.5 | |
| 156.4 | 8,695.2 | 4,423.4 | 309.4 | 9.2 | 16.8 | 28.6 | 4.5 | |
| 171.2 | 10,978.1 | 16,084.1 | 1,196.9 | 10.9 | 17.4 | 9.6 | 1.6 |
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex... rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. Address: 1261 Liberty Way, Vista, CA, United States, 92081 Read more
Executive Chairman of the Board of Directors
Dr. Tina S. Nova Ph.D.
Executive Chairman of the Board of Directors
Dr. Tina S. Nova Ph.D.
Headquarters
Vista, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Exagen Inc (XGN) stood at $ 54 Mln as on 31-Mar-25
The share price of Exagen Inc (XGN) is $7.36 (NASDAQ) as of 18-Jun-2025 16:00 EDT. Exagen Inc (XGN) has given a return of 13.98% in the last 3 years.
Exagen Inc (XGN) has a market capitalisation of $ 169 Mln as on 18-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Exagen Inc (XGN) is 26.38 times as on 18-Jun-2025, a 892% premium to its peers’ median range of 2.66 times.
Since, TTM earnings of Exagen Inc (XGN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Exagen Inc (XGN) and enter the required number of quantities and click on buy to purchase the shares of Exagen Inc (XGN).
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. Address: 1261 Liberty Way, Vista, CA, United States, 92081
The CEO & director of Dr. Tina S. Nova Ph.D.. is Exagen Inc (XGN), and CFO & Sr. VP is Dr. Tina S. Nova Ph.D..
There is no promoter pledging in Exagen Inc (XGN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,204
|
|
|
1,110
|
|
|
1,044
|
|
|
859
|
|
|
803
|
|
|
555
|
|
|
519
|
|
|
434
|
|
|
342
|
| Exagen Inc. (XGN) | Ratios |
|---|---|
|
Return on equity(%)
|
-160.94
|
|
Operating margin(%)
|
-17.73
|
|
Net Margin(%)
|
-27.34
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Exagen Inc (XGN) was $0 Mln.
$-0.37
(
